“…Neutral results, primarily on early post-ROSC arterial pressure and inflammatory response, strongly implied a resistance to previously well-documented, circulatory and immunomodulatory effects of steroids [ 3 ]. Nevertheless, single, high-dose (i.e., 250 mg) methylprednisolone within 5–30 min following successful out-of-hospital ALS has been recently associated with lower postresuscitation interleukin-6, improved postresuscitation hemodynamics and higher probability of survival to discharge [ 4 , 5 ]; these benefits might reflect a rapid, nongenomic, high-dose methylprednisolone action [ 4 ].…”